A groundbreaking blood test capable of detecting various cancers early, even before symptoms arise, could revolutionize cancer diagnosis within the healthcare system, according to experts.
Trials of the Galleri test, designed to screen for over 50 types of cancer, demonstrated an accuracy rate of 62% in detecting potential cases and a remarkable 99.6% accuracy in ruling out cancer in individuals without the disease.
The promising outcomes from the US trial coincide with ongoing NHS trials of the Galleri test, which could potentially become the first multi-cancer blood test, often referred to as the “Holy Grail” by medical researchers.
Sir Harpal Kumar, president of International Business and BioPharma at Grail, the company behind Galleri, expressed enthusiasm about the test’s potential to significantly improve cancer outcomes by detecting a higher number of cancers at earlier stages, complementing existing screening methods.
Currently, the NHS offers screening for only four types of cancer through various methods like scans or biopsies, but the introduction of multi-cancer early detection tests like the Galleri test and miONCO-Dx could transform cancer screening by identifying multiple cancers simultaneously from a single blood sample.
The Galleri test, intended for annual use, scans for unique cancer DNA signatures in the blood, providing early indications of potential cancer presence. Notably, a major US trial involving 23,000 asymptomatic participants revealed that 61.6% of individuals with a detected “cancer signal” in their blood later received a cancer diagnosis.
Despite the promising results, Professor Anna Schuh from the University of Oxford noted that the test’s accuracy is not perfect, with approximately half of positive results turning out to be false alarms. However, the test’s ability to pinpoint the origin of cancer in 92% of cases could streamline diagnostic processes and potentially reduce costs associated with additional scans and tests.
The ongoing research on the effectiveness of tests like Galleri in reducing cancer-related deaths remains crucial, as highlighted by experts in the field. The potential impact of such innovative screening methods on cancer diagnosis and treatment outcomes is a topic of growing interest within the medical community.
The latest findings on the Galleri test and its implications for cancer detection and management are being presented at the European Society for Medical Oncology (ESMO) Congress in Berlin, underscoring the significance of early detection in improving cancer care.